Skip to main content

Regulatory and Washington

  • Hyperion buys rights to drug for rare genetic diseases

    SOUTH SAN FRANCISCO, Calif. — Hyperion Therapeutics has purchased rights to a drug for treating genetic metabolic disorders, the company said.

    Hyperion announced the purchase of Ravicti (glycerol phenylbutyrate) from Ucyclyd Pharma, a subsidiary of Medicis Pharmaceutical.

  • Court dismisses AstraZeneca case against FDA

    NEW YORK — A federal court has dismissed a case that drug maker AstraZeneca filed against regulators regarding a drug used to treat psychotic and bipolar disorders, the company said Monday.

  • Readers’ PBM perspectives

    A guest column in the March 12 issue of DSN, “Let me tell you what PBMs do,” by Republican Utah State Rep. Evan Vickers, really set off a firestorm of debate on DrugStoreNews.com and on DSN’s social media sites. Check out this snippet from two online users with VERY different perspectives on all of this. For Rep. Vickers’ complete column and to add your own views to the debate, click here.


  • Supreme Court hears arguments surrounding healthcare law

    WASHINGTON — The U.S. Supreme Court justices have gathered this week to discuss a potential legal issue surrounding President Obama's healthcare law.

  • Ninth Circuit Court of Appeals denies attempt to reinstate Medi-Cal cuts

    ALEXANDRIA, Va. — The Ninth Circuit Court of Appeals ruled in favor of healthcare providers, denying a request by the California Department of Health Care Services to suspend a preliminary injunction that currently is preventing the implementation of Medi-Cal cuts.

  • Suppliers, FDA shine spotlight on switches

    The recent Food and Drug Administration public meeting on driving future switch potential by way of the pharmacist and/or health technology sparked some discussion on what’s next.


  • FDA approves Teva allergy drug

    JERUSALEM — The Food and Drug Administration has approved a drug made by Teva for treating allergies, the company said Monday.

    Teva announced the approval of Qnasl (beclomethasone dipropionate) for seasonal and year-round nasal allergies in patients ages 12 years and older. The company said the drug, a "dry" nasal aerosol, would become available next month.

  • Report: Metformin cost-effective strategy in battling diabetes

    ALEXANDRIA, Va. — Lifestyle intervention and treatment with metformin provide safe, long-term, cost-effective means of preventing Type 2 diabetes and should be incorporated into prevention strategies for reducing the dramatic rise in incidence of Type 2 diabetes in the United States, according to two new analyses and an editorial published in the April issue of Diabetes Care.

X
This ad will auto-close in 10 seconds